French researcher resident in the USA, Michel Sadelain has developed a highly promising immunotherapy strategy that combines gene and cell therapy to provide tailormade cancer treatment to patients.
Sadelain is the Director of the Center for Cell Engineering at the Memorial Sloan-Kettering Cancer Center in New York. Together with Isabelle Rivière, he has developed Car-T Cell Therapy: an immunotherapy strategy based on the production of "improved" white blood cells, which are obtained by genetically modifying the patient’s own cells.
When he presented his idea for the first time more than 20 years ago, no-one really took him seriously! Yet this approach, now used in the treatment of pediatric and young adult leukemia and adult lymphomas, is eliciting a great deal of hope.